https://endpts.com/q32-bio-to-take-homology-medicines-nasdaq-spot-to-fund-phii-trials-in-autoimmune-inflammatory-conditions/
0
0
11/16/23 at 1:44pm
Organization
Endpoints News
Author
Kyle LaHucik
The reverse mergers are flowing. Q32 Bio will take Homology Medicines’ place on the Nasdaq, the companies said Thursday morning, and the biologics maker expects to have about $115 million at the time their deal closes. The Massachusetts biotechs follow Lenz T…
Create an account
or login to join the discussion